DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Vulvovaginal
Candidiasis – Pipeline Review, H2 2016” report to their
Vulvovaginal Candidiasis pipeline therapeutics constitutes close to 10
molecules. Out of which approximately 10 molecules are developed by
Companies. Our latest report Vulvovaginal Candidiasis – Pipeline Review,
H2 2016, outlays comprehensive information on the therapeutics under
development for Vulvovaginal Candidiasis, complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
Vulvovaginal Candidiasis refers to a disorder characterized by signs and
symptoms of vulvovaginal inflammation in the presence of Candida
species. Symptoms of vulvovaginal candidiasis include itching, soreness
and/or burning discomfort in the vagina and vulva, heavy white curd-like
vaginal discharge, bright red rash affecting inner and outer parts of
the vulva, sometimes spreading widely in the groin to include pubic
areas, inguinal areas and thighs. The molecules developed by Companies
in Phase II, Phase I and Preclinical stages are 7, 2 and 1 respectively.
Furthermore, this report also reviews of key players involved in
therapeutic development for Vulvovaginal Candidiasis and features
dormant and discontinued projects.
Key Topics Covered:
- Vulvovaginal Candidiasis Overview
- Therapeutics Development
- Pipeline Products for Vulvovaginal Candidiasis – Overview
- Pipeline Products for Vulvovaginal Candidiasis – Comparative Analysis
- Vulvovaginal Candidiasis – Therapeutics under Development by Companies
Vulvovaginal Candidiasis – Therapeutics under Investigation by
- Vulvovaginal Candidiasis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Vulvovaginal Candidiasis – Products under Development by Companies
Vulvovaginal Candidiasis – Products under Investigation by
Vulvovaginal Candidiasis – Companies Involved in Therapeutics
- Cidara Therapeutics, Inc.
- Grupo Ferrer Internacional, S.A.
- NovaDigm Therapeutics, Inc.
- Scynexis, Inc.
- Viamet Pharmaceuticals, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/pg2v24/vulvovaginal
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716